Targeting IL ‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years
Allergy · 2024-06 · 79 (6) · 1560-1572
DOI: 10.1111/all.16108 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 02.04.2024. Verfasst von Emma Guttman-Yassky und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-13, Antibodies, Monoclonal, Biomarkers. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: LEO Pharma A/S, LEO Pharma.
Abstract (Originalsprache)
Background
Tralokinumab is a monoclonal antibody that specifically neutralizes interleukin (IL)‐13, a key driver of skin inflammation and barrier abnormalities in atopic dermatitis (AD). This study evaluated early and 2‐year impacts of IL‐13 neutralization on skin and serum biomarkers following tralokinumab treatment in adults with moderate‐to‐severe AD.
Methods
Skin biopsies and blood samples were evaluated from a subset of patients enrolled in the Phase 3 ECZTRA 1 (NCT03131648) and the long‐term extension ECZTEND (NCT03587805) trials. Gene expression was assessed by RNA sequencing; protein expression was assessed by immunohistochemistry and immunoassay.
Results
Tralokinumab improved the transcriptomic profile of lesional skin by Week 4. Mean improvements in the expression of genes dysregulated in AD were 39% at Week 16 and 85% at 2 years with tralokinumab, with 15% worsening at Week 16 with placebo. At Week 16, tralokinumab significantly decreased type 2 serum biomarkers (CCL17/TARC, periostin, and IgE), reduced epidermal thickness versus placebo, and increased loricrin coverage versus baseline. Two years of tralokinumab treatment significantly reduced expression of genes in the Th2 ( IL4R , IL31 , CCL17 , and CCL26 ), Th1 ( IFNG ), and Th17/Th22 ( IL22 , S100A7 , S100A8 , and S100A9 ) pathways as well as increased expression of epidermal differentiation and barrier genes ( CLDN1 and LOR ). Tralokinumab also shifted atherosclerosis signaling pathway genes ( SELE , IL‐37 , and S100A8 ) toward non‐lesional expression.
Conclusion
Tralokinumab treatment improved epidermal pathology, reduced systemic markers of type 2 inflammation, and shifted expression of key AD biomarkers in skin towards non‐lesional levels, further highlighting the key role of IL‐13 in the pathogenesis of AD. Clinical Trial Registration NCT03131648, NCT03587805.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Dermatology, University Hospital of Lille, INFINITE (Institute for Translational Research) U1286 Inserm, University of Lille, Lille, France.
- University of California, San Diego School of Medicine, San Diego, California, USA.
- Klinische Forschung Osnabrück, Osnabrück, Germany.
- Mount Sinai Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Emma Guttman-Yassky
Förderung
- LEO Pharma A/S
- LEO Pharma
Zitieren
APA
Guttman-Yassky, E., Kabashima, K., Staumont-Salle, D., Nahm, W. K., Pauser, S., Da Rosa, J. C., Martel, B. C., Madsen, D. E., Røpke, M., Arlert, P., Steffensen, L., Blauvelt, A., & Reich, K. (2024). Targeting IL ‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy, 79(6), 1560-1572. https://doi.org/10.1111/all.16108
Vancouver
Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm WK, Pauser S, Da Rosa JC, et al. Targeting IL ‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560-1572. doi:10.1111/all.16108
BibTeX
@article{GuttmanYassky2024,
author = {Guttman-Yassky, Emma and Kabashima, Kenji and Staumont-Salle, Delphine and Nahm, Walter K and Pauser, Sylvia and Da Rosa, Joel Correa and Martel, Britta Cathrina and Madsen, Daniel Elenius and Røpke, Mads and Arlert, Petra and Steffensen, Louise and Blauvelt, Andrew and Reich, Kristian},
title = {Targeting IL ‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years},
journal = {Allergy},
year = {2024},
volume = {79},
number = {6},
pages = {1560--1572},
doi = {10.1111/all.16108}
}
EUVIMED